Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Millennium Pharmacon International Tbk's revenue for the
three
months ended in Mar. 2026 was Rp1,017,973 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was Rp4,147,596 Mil.
PT Millennium Pharmacon International Tbk's Revenue per Share for the
three
months ended in Mar. 2026 was Rp799.04.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was Rp3,255.57.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
PT Millennium Pharmacon International Tbk Revenue Related Terms
PT Millennium Pharmacon International Tbk Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Millennium Pharmacon International Tbk Revenue Chart
PT Millennium Pharmacon International Tbk Annual Data
For the Medical Distribution subindustry, PT Millennium Pharmacon International Tbk's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Millennium Pharmacon International Tbk Revenue vs Medical Distribution Industry
PT Millennium Pharmacon International Tbk Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp4,147,596 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Millennium Pharmacon International Tbk (ISX:SDPC) has a Revenue of Rp4,147,596 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on PT Millennium Pharmacon International Tbk and its competitors.
Is PT Millennium Pharmacon International Tbk's Revenue too high?
PT Millennium Pharmacon International Tbk's current Revenue is Rp4,147,596 Mil. Overall, PT Millennium Pharmacon International Tbk has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Millennium Pharmacon International Tbk's Revenue compare to MCK and COR?
PT Millennium Pharmacon International Tbk's Revenue of Rp4,147,596 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Distribution company?
A good Revenue depends on the Medical Distribution industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on PT Millennium Pharmacon International Tbk and its competitors. PT Millennium Pharmacon International Tbk's current Revenue is Rp4,147,596 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Millennium Pharmacon International Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk (ISX:SDPC) is currently considered Fairly Valued. The stock's GF Value™ is Rp166.83, compared to a current price of Rp181.00 — trading 8.5% above its estimated fair value. The current Revenue is Rp4,147,596 Mil. PT Millennium Pharmacon International Tbk's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For PT Millennium Pharmacon International Tbk (ISX:SDPC), the current Revenue is Rp4,147,596 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Millennium Pharmacon International Tbk (ISX:SDPC) Overvalued in 2026?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk stock appears to be overvalued.
The current stock price of Rp181.00 is trading 8.5% above its estimated GF Value™ of Rp166.83.
GuruFocus considers PT Millennium Pharmacon International Tbk to be Fairly Valued.
Key valuation signals for ISX:SDPC:
Revenue: Rp4,147,596 Mil
GF Value™: Rp166.83 vs. price of Rp181.00 (8.5% above fair value)
No single metric tells the full story. See the ISX:SDPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressJl. Sultan Iskandar Muda No 18/Jl. Bungur No. 1, Crown Bungur Arteri Lantai 2-4, Kel. Kebayoran Lama Selatan, Kec. Kebayoran Lama, South Jakarta, Jakarta, IDN, 12240
PT Millennium Pharmacon International Tbk is engaged in distributing medicines, food supplements, and medical disposables. The group's operating segments are Prescription medicine, Non-prescription medicine, Medical Disposables, and others, of which the majority of revenue is derived from the Prescription Medicine segment. The company's geographical segments are Jawa, Sumatra, Kalimantan, Sulawesi, and Bali & Lombok.
79GF Score
Get the complete analysis for ISX:SDPC
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SDPC has been successfully added to your 
